Table 4—

Meta-analysis of the studies including surgical stage nonsmall cell lung cancer (NSCLC), with their characteristics

First author [ref. no.]	Method	QS %	Patients n	p53+ %	HR	95% CI
Carbone 20	PCR-;SSCP	52	85	53	0.88	0.46–1.67
Dalquen 22	IHC	54	215	47	1.37	0.99–1.89
Ebina 26	IHC-;DO-;7	55	138	36	3.55	1.54–8.22
Esposito 27	IHC-;DO-;7	53	61	36	2.15	1.06–4.38
Fontanini 29	IHC-;1801	57	48	48	2.63	1.29–5.38
Fontanini 30	IHC-;1801	52	107	50	2.02	1.07–3.82
Fujino 32	IHC-;DO-;7	70	63	57	1.80	0.99–3.25
Geradts 34	IHC-;DO-;7	52	103	49	0.83	0.49–1.42
Horio 42	PCR-;SSCP	52	71	49	2.45	1.32–4.55
Ishida 45	IHC-;DO-;7	72	114	39	2.30	0.56–9.19
Kim 10	IHC	79	62	NC	0.90	0.30–2.70
Laudanski 56	IHC-;DO-;7	78	84	55	2.69	1.31–5.52
Lavezzi 57	IHC–1801	52	152	16	1.25	0.69–2.26
Lee 58	IHC-;DO-;7	63	156	65	1.06	0.61–1.84
Moldvay 68	IHC	45	83	55	2.54	1.22–5.29
Morkve 69	IHC-;1801	57	112	77	1.41	0.74–2.70
Nishio 71	IHC-;DO-;7	63	208	46	1.08	0.73–1.60
Top 88	PCR-;DGGE	46	46	67	2.51	0.96–6.56
Tormämen 89	IHC	49	71	52	2.41	1.40–4.16
Vega 90	PCR-;SSCP	63	62	26	3.02	1.05–8.68
Overall
Fixed-effects model		54	2041	48	1.56	1.37–1.79
Random-effects model					1.66	1.37–2.01

QS: quality score
p53+: presence of an abnormality of p53
HR: hazard ratio
CI: confidence interval
PCR: polymerase chain reaction
SSCP: single-strand conformation polymorphism method
IHC: immunohistochemistry with antibodies other than DO-;7 or 1801
IHC-;DO-;7: immunohistochemistry with monoclonal antibody DO-;7
IHC-;1801: immunohistochemistry with monoclonal antibody 1801
DGGE: denaturing gradient gel electrophoresis
For group of NSCLC, surgically resected n=20
Chi-;squared statistic for heterogeneity = 33.82, 19 degrees of freedom, p=0.02